Advertisement

Correction to: Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study

  • Hidenobu TaniharaEmail author
  • Takahiko Kakuda
  • Tetsuro Sano
  • Takashi Kanno
  • Ryosuke Imada
  • Wataru Shingaki
  • Ryoji Gunji
Correction
  • 145 Downloads

Correction to: Adv Ther (2019) 36:333–343  https://doi.org/10.1007/s12325-018-0863-1

In the original publication values in the results section are incorrect. Errors were also identified in Fig. 5. Both the updated results sections and Fig. 5 are provided below.
Fig. 5

Intraocular pressure changes in patients according to treatment initiation patterns. IOP intraocular pressure

Results

Treatment Initiation Patterns with Ripasudil

In the 3016 eyes (patients) included in the efficacy analysis, the numbers of patients classified as “Add-on (only)”, “Add-on (with other glaucoma drug)”, “Switch from prior treatment”, “Initial monotherapy” and “Initial combination therapy” were 2224 (73.7%), 27 (0.9%), 385 (12.8%), 326 (10.8%) and 54 (1.8%), respectively. The mean number ± SD of glaucoma medicines concomitantly used by patients was 2.3 ± 1.0.

Efficacy

Changes in IOP were also analysed according to the treatment initiation patterns (Fig. 5). IOP was significantly reduced in all groups: – 2.8 ± 4.2 mmHg in 313 eyes in the “Initial monotherapy” group, – 6.7 ± 9.4 mmHg in 42 eyes in the “Initial combination therapy” group, – 1.9 ± 4.2 mmHg in 362 eyes in the “Switch from prior treatment” group, – 2.5 ± 3.8 in 2100 eyes in the “Add-on (only)” group, and – 3.8 ± 4.0 mmHg in 22 eyes in the “Add-on (with other glaucoma drug” group.

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Hidenobu Tanihara
    • 1
    Email author
  • Takahiko Kakuda
    • 2
  • Tetsuro Sano
    • 2
  • Takashi Kanno
    • 2
  • Ryosuke Imada
    • 2
  • Wataru Shingaki
    • 2
  • Ryoji Gunji
    • 2
  1. 1.Kumamoto University HospitalKumamotoJapan
  2. 2.Post Marketing Surveillance DepartmentKowa Company, Ltd.TokyoJapan

Personalised recommendations